Cyprus Sees a Surge In Tourism Revenue: February’s Significant Gains And What It Means

by News Editor

April 29, 2025

In February 2025, Cyprus reported a notable €79.7 million in tourism revenue, reflecting a remarkable 22.4% increase from the same period last year when earnings stood at €65.1 million, according to the latest release by the statistical service.

Year-to-Date Performance

Taking a broader view, the combined revenue for the first two months of 2025 reached €148.9 million, soaring by 35% compared to €110.3 million during the same months in 2024.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Spending Patterns of Tourists

The per capita expenditure for February rose by 14.3%, amounting to €595.71 compared to €521.01 in February 2024. Among the tourists, British visitors, accounting for 24.8% of the arrivals, spent an average of €73.42 per day. Polish tourists made up 15.1% of the total arrivals and spent €71.07 daily. Intriguingly, visitors from Israel had the highest daily spending at €203.06.

Future Prospects

Looking ahead, Harris Papacharalambous, President of Cyprus Travel and Tourism Agents Association, anticipates that a total of 4.25 million tourists will visit Cyprus by the end of the year. The vision for 2026 is to enhance the island’s tourism offerings with innovative changes, turning it into a regional hub for tourism activities, thanks to Cyprus’ strategic geographical position.

For further exploration of Cyprus’s rapid growth and economic potential, read about Cyprus’s fastest-growing tech companies and their global impact.

The Future Forbes Realty Global Properties

Anthropic Acquires Coefficient Bio In $400 Million Stock Deal

by THEFUTURE.TEAM

April 6, 2026

Anthropic acquired biotech AI startup Coefficient Bio in a deal valued at approximately $400 million in stock, according to people familiar with the matter. Sources confirmed the transaction, although detailed financial terms were not publicly disclosed.

Deepening Forays Into Healthcare And Life Sciences

The acquisition follows Anthropic’s earlier launch of Claude for Life Sciences, a tool designed to support scientific research and drug discovery. The deal expands the company’s activity in healthcare and biotechnology. Anthropic is increasing its focus on applying AI models to scientific workflows, including data analysis and experimental design. Expansion into life sciences reflects broader industry trends.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Transforming Computational Drug Discovery

Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan C. Frey, both former researchers at Genentech’s Prescient Design group. The company focused on applying AI to drug discovery and biological research processes. Its technology aims to improve efficiency in identifying drug candidates and analyzing biological data. Early-stage development reflects growing interest in AI-driven research tools.

Strategic Talent And Expertise Integration

Around 10 employees from Coefficient Bio will join Anthropic following the acquisition, strengthening its health and life sciences team. The group will contribute to the development of AI models for scientific and medical applications. Access to specialized talent supports the expansion of capabilities in drug discovery and biological research.

Industry Context And Outlook

Investment in AI for drug discovery has increased as companies seek to reduce development timelines and costs. Large technology firms and startups are expanding activity in this area. Further developments will depend on how effectively Anthropic integrates the team and advances its life sciences strategy.

Breaking news